TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Sunday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

TherapeuticsMD stock opened at $1.62 on Friday. The business’s fifty day simple moving average is $1.79 and its two-hundred day simple moving average is $2.05. TherapeuticsMD has a 12 month low of $1.43 and a 12 month high of $4.03.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC bought a new stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned 2.57% of TherapeuticsMD at the end of the most recent quarter. Institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.